Although he started out at Pitzer College in Claremont, California, as a philosophy and English double major, Andrew Scheyer switched directions about halfway through to neuroscience, thinking the field contained more-definitive answers. He was partly right about that, and for the open questions that remained, he now had the tools to find some of those answers himself. Over the summer of 2009, he interned with the Multidisciplinary Association for Psychedelic Studies (MAPS) in Santa Cruz, where researchers were conducting a pilot study using MDMA (also known as ecstasy) to treat posttraumatic stress disorder (PTSD)—a project that recently entered Phase 3 trials. “It was an enlightening experience to see where neuroscience could be affecting people.”
As a PhD student at Rosalind Franklin University of Medicine and Science in North Chicago, he worked with Marina Wolf and Kuei Tseng on the regulation of glutamate receptors called AMPA receptors in rats during withdrawal ...
